Skip to main content
SpringerLink
Log in

Testosterone Therapy

  • Chapter
Andrology

Abstract

Male hypogonadism is the main indication for testosterone. Table 21.1 provides an overview of other possible applications. Some of these applications are dealt with in other chapters of this volume, for example in constitutionally delayed puberty (Chap. 12), in late-onset hypogonadism (LOH) (Chap. 14), in male hormonal contraception (Chap. 29) and in idiopathic male infertility (Chap. 22). In addition, this chapter deals with its use in excessively tall stature (Sect. 21.5) and with its abuse in doping and body building (Sect. 21.6). Because of its erythropoetic effect testosterone is also licensed for the treatment of aplastic and renal anemia, but lost ground to erythropoetin after the latter was introduced. For treatment of this condition, the reader is referred to textbooks of internal medicine.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 139.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Allan CA, Strauss BJ, Burger HG, Forbes EA, McLachlan RI (2008) Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab 93:139–146

    Article  CAS  PubMed  Google Scholar 

  • Akcam T, Bolu E, Merati AL, Durmus C, Gerek M, Ozkaptan Y (2004) Voice changes after androgen therapy for hypogonadotrophic hypogonadism. Laryngoscope 114:1587–1591

    Article  CAS  PubMed  Google Scholar 

  • Bagchus WM, Hust R, Maris F, Schnabel PG, Houwing NS (2003) Important effect of food on the bioavailability of oral testosterone undecanoate. Pharmacotherapy 23:319–325

    Article  CAS  PubMed  Google Scholar 

  • Bals-Pratsch M, Knuth UA, Yoon YD, Nieschlag E (1986) Transdermal testosterone substitution therapy for male hypogonadism. Lancet ii:943–946

    Article  Google Scholar 

  • Barratt-Connor E, von Mühlen DG, Kritz-Silverstein D (1999) Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo study. J Clin Endocrinol Metab 84:573–577

    Article  Google Scholar 

  • Behre HM, Böckers A, Schlingheider A, Nieschlag E (1994a) Sustained suppression of serum LH, FSH testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal man. Clin Endocrinol 40:241–248

    Article  CAS  Google Scholar 

  • Behre HM, Bohmeyer J, Nieschlag E (1994b) Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal contrals. Clin Endocrinol 40:341–349

    Article  CAS  Google Scholar 

  • Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E (1997) Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 82:2386–2390

    Article  CAS  PubMed  Google Scholar 

  • Behre HM, Abshagen K, Oettel M, Hübler D, Nieschlag E (1999a) Intramuscular injection of testosterone undecanoate for the treatment of male hypogonadism: phase I-studies. Eur J Endocrinol 140:414–419

    Article  CAS  PubMed  Google Scholar 

  • Behre HM, von Eckardstein S, Kliesch S, Nieschlag E (1999b) Long-term substitution therapy of hypogonadal men with transscrotal testosterone over seven to ten years. Clin Endocrinol 50:629–635

    Article  CAS  Google Scholar 

  • Behre HM, Wang C, Handelsman DJ, Nieschlag E. (2004) Pharmacology of testosterone preparations. In: Nieschlag E, Behre HM (eds) Testosterone -Action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 405–444

    Chapter  Google Scholar 

  • Beutel ME, Wiltink J, Hauck EW, Auch D, Behre HM, Brähler E, Weidner W, The Hypogonadism Investigator Group (2005) Correlations between hormones, physical, and affective parameters in aging urologic outpatients. Eur Urol 47:749–755

    Article  CAS  PubMed  Google Scholar 

  • Bhasin S (2004) Testosterone effects on the skeletal muscle. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 3rd edn. Cambrindge University Press, Cambridge, pp 255–282

    Chapter  Google Scholar 

  • Butenandt A, Hanisch G (1931) Umwandlung des Dehydroan-drosterons in Androstendiol und Testosteron; ein Weg zur Darstellung des Testosterons aus Cholesterin. Hoppe-Seylers's Z Physiol Chem 231:289–98

    Google Scholar 

  • Calof OM, Singh AB, Lee ML, Kenny AM, Urban RJ, Tenover JL, Bhasin S (2005) Adverse events associated with testosterone replacement in middle-aged and older men: A metaanalysis of randomized, placebo-controlled trials. J Gerontol A Biol Sci Med Sci 69:1451–1457

    Google Scholar 

  • Cherrier MM, Asthana S, Plymate S, Baker L, Matsumoto AM, Peskind E, Raskind MA, Brodkin K, Bremner W, Petrova A, LaTendresse S, Craft S (2001) Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology 57:80–88

    CAS  PubMed  Google Scholar 

  • Choong K, Lakshman KM, Bhasin S (2008) The physiological and pharmacological basis for the ergogenic effects of androgens on elite sports. Asain J Androl 10:351–363

    Article  CAS  Google Scholar 

  • Christiansen K (2004) Behavioural correlates of testosterone. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 125–172

    Chapter  Google Scholar 

  • Cunningham GR, Hirshkowitz M, Kroenman SG, Karacan I (1990) Testosterone replacement therapy and sleep-related erections in hypogonadal men. J Clin Endocrinol Metab 70:792–797

    Article  CAS  PubMed  Google Scholar 

  • de Waal WJ, Vreeburg JTM, Bekkering F, de Jong FH, de Muinck Keizer-Schrama SMPF, Drop SLS, Weber RFA (1995) High-dose testosterone therapy for reduction of final height in constitutionally tall boys: Does it influence testicu-lar function in adulthood? Clin Endocrinol 43:87–95

    Article  Google Scholar 

  • Delanoe D, Fougevrollas B, Meyer L, Thonneau P (1984) Androgenisation of female partners of men on medroxypro-gesterone acetate/percutaneous testosterone contraception. Lancet 1:276

    Article  CAS  PubMed  Google Scholar 

  • Drop SLS, de Waal J, de Muinck Keizer-Schrama SMPF (1998) Sex steroid treatment of constitutionally tall stature. Endocr Rev 19:540–558

    Article  CAS  PubMed  Google Scholar 

  • Finkelstein JS, Klibanski A, Neer RM, Doppelt SH, Rosenthal DI, Segre GV, Crowley W jr (1989) Increases in bone density during treatment of men with idiopathic hypogonadotro-pic hypogonadism. J Clin Endocrinol Metab 69:776–783

    Article  CAS  PubMed  Google Scholar 

  • Gao W, Dalton JT (2007) Expanding the therapeutic use of androgens via selective androgen receptor modulators (SARMs). Drug Discov Today 12:241–248

    Article  CAS  PubMed  Google Scholar 

  • Gooren LJG (1998) A ten year safety study on the oral androgen testosterone undecanoate. J Androl 15:212–215

    Google Scholar 

  • Gooren LJ, Behre HM, Saad F, Frank A, Schwerdt S (2007) Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research. Aging Male 10:173–181

    Article  CAS  PubMed  Google Scholar 

  • Hajjar RR, Kaiser FE, Morley JE (1997) Outcomes of long term testosterone replacement in older hypogonadal males: A retrospective analysis. J Clin Endocrinol Metab 82:3793–3796

    Article  CAS  PubMed  Google Scholar 

  • Isidori AM, Giannetta E, Greco EA, Gianfrilli D, Bonifacio V, Isidori A, Lenzi A, Fabbri A (2005) Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: A meta-analysis. Clin Endocrinol 63:280–293

    Article  CAS  Google Scholar 

  • Jockenhövel F, Vogel E, Reinhardt W, Reinwein D (1997) Effects of various modes of androgen substitution therapy on eryth-ropoiesis. Eur J Med Res 2:293–298

    PubMed  Google Scholar 

  • Jockenhövel F, Bullmann C, Schubert M, Vogel E, Reinhardt W, Reinwein D, Müller-Wieland D, Krone W (1999) Influence of various modes of androgen substitution on serum lipids and lipoproteins in hypogonadal men. Metabolism 48:590–596

    Article  PubMed  Google Scholar 

  • Kelleher S, Turner, L, Howe C, Conway AJ, Handelsman DJ (1999) Extrusion of testosterone pellets: A randomized controlled clinical study. Clin Endocrinol 51:469–471

    Article  CAS  Google Scholar 

  • Kelleher S, Conway AJ, Handelsman DJ (2004) Blood testosterone threshold for androgen deficiency symptoms. J Clin Endocrinol Metab 89:3813–3817

    Article  CAS  PubMed  Google Scholar 

  • King DS, Sharp RL, Vukovich MD, Brown GA, Reifenrath TA, Uhl NL, Parsons KA (1999) Effect of oral androstenedione on serum testosterone and adaptations to resistance training in young men: A randomized controlled trial. JAMA 281:2020–2028

    Article  CAS  PubMed  Google Scholar 

  • Kistler L (2006) Todesfälle bei Anabolikamissbrauch. Dissertation, München

    Google Scholar 

  • Knuth UA, Maniera H, Nieschlag E (1989) Anabolic steroids and semen parameters in body builders. Fertil Steril 52:1041–1047

    CAS  PubMed  Google Scholar 

  • Kochakian CD (ed) (1976) Anabolic androgenic steroids. Handbook of experimental harmacology, vol. 43. Springer, Berlin

    Google Scholar 

  • Korbonits M, SlawikM, Cullen D, Ross RJ, StallaG, SchneiderH, Reincke M, Bouloux PM, Grossmann AB (2004) A comparison of a novel testosterone bioadhesive buccal system, Striant, with a testosterone adhesive patch in hypogonadal males. J Clin Endocrinol Metab 89:2039–2043

    Article  CAS  PubMed  Google Scholar 

  • Kühnert B, Byrne M, Simoni M, Köpcke W, Gerss J, Lemmnitz G, Nieschlag E (2005) Testosterone substitution with a new transdermal, hydroalcoholic gel applied to scrotal or non-scrotal skin: A multicentre trial. Eur J Endocrinol 153:317–326

    Article  PubMed  Google Scholar 

  • Leifke E, Körner HC, Link TM, Behre HM, Peters PE, Nieschlag E (1998) Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men. Eur J Endocrinol 138:51–58

    Article  CAS  PubMed  Google Scholar 

  • Lemcke B, Zentgraf J, Behre HM, Kliesch S, Nieschlag E (1996) Long-term effects on testicular function of high-dose testosterone treatment for excessively tall stature. J Clin Endocrinol Metab 81:296–301

    Article  CAS  PubMed  Google Scholar 

  • McGriff-Lee NJ (2002) Transdermal testosterone gel (Cellegy). Curr Opin Investig Drugs 3:1629–1632

    CAS  PubMed  Google Scholar 

  • McNicholas T, Ong T (2006) Review of Testim gel. Expert Opin Pharmacother 7:477–484

    Article  CAS  PubMed  Google Scholar 

  • Meikle AW (1998) A permeation-enhanced non-scrotal testosterone transdermal system for the treatment of male hypogonadism. In: NieschlagE,BehreHM(eds)Testosterone-action, deficiency, substitution, 2nd edn. Springer, Heidelberg, pp 389–422

    Google Scholar 

  • Morales A Johnston B, Heaton JP, Lundie M (2007) Testosterone supplementation for hypogonadal impotence assessment of biochemical measures and therapeutic outcomes. J Urol 157:849–854

    Article  Google Scholar 

  • Nieschlag E (1981) Ist die Anwendung von Methyltestosteron obsolet? Dtsch Med Wschr 106:1123–1125

    Article  CAS  PubMed  Google Scholar 

  • Nieschlag E (1992) Testosteron, Anabolika und aggressives Verhalten bei Männern. Dtsch Ärztebl 89:2967–2972

    Google Scholar 

  • Nieschlag E (2006) Testosterone treatment comes of age: New options for hypogonadal men. Clin Endocrinol 65:275–281

    Article  CAS  Google Scholar 

  • Nieschlag E, Behre HM (eds) (2004) Testosterone — action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge

    Google Scholar 

  • Nieschlag E, Behre HM (2004) Clinical use of testosterone in hypogonadism and other conditions. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution. 3rd edn. Cambridge University Press, Cambridge, pp 375–404

    Chapter  Google Scholar 

  • Nieschlag E, Wang CH, Handelsman DJ, Swerdloff RS, Wu FCW, Einer-Jensen N, Khanna J, Waites GMH, World Health Organization (eds) (1992) Guidelines for the use of androgens. WHO, Geneva

    Google Scholar 

  • Nieschlag E, Nieschlag S, Behre HM (1993) Life expectancy and testosterone. Nature 366:215

    Article  CAS  PubMed  Google Scholar 

  • Nieschlag E, Büchter D, von Eckardstein S, Abshagen K, Behre HM (1999) Repeated intramuscular injections of testosterone undecanoate for substitution therapy of hypogo-nadal men. Clin Endocrinol 51:757–763

    Article  CAS  Google Scholar 

  • Nieschlag E, Behre HM, Bouchard P, Corrales JJ, Jones TH, Stalla GK, Webb SM, Wu FC (2004) Testosterone replacement therapy: Current trends and future directions. Hum Reprod Update 10:409–419

    Article  CAS  PubMed  Google Scholar 

  • Nieschlag E, Swerdloff R, Behre HM, Gooren LJ, Kaufman JM, Legros JJ, Lunenfeld B, Morley JE, Schulman C, Wang C, Weidner W, Wu FC (2006) Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendations. Int J Androl 27:135–137

    Article  CAS  Google Scholar 

  • O'Connor DB, Archer J, Hair WM, Wu FC (2002) Exogenous testosterone, aggression, and mood in eugonadal and hypog-onadal men. Physiol Behav 75:557–566

    Article  PubMed  Google Scholar 

  • Randall VA (2004) Androgens and hair. In: Nieschlag E, Behre HM (eds) Testosterone -Action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 207–231

    Chapter  Google Scholar 

  • Rolf C, von Eckardstein S, Koken U, Nieschlag E (2002) Testosterone substitution of hypogonadal men prevents the age-dependent increases in body mass index, body fat and leptin seen in healthy ageing men: Results of a cross-sectional study. Eur J Endocrinol 146:505–511

    Article  CAS  PubMed  Google Scholar 

  • Ruzicka L, Wettstein A (1935) Synthetische Darstellung des Testishormons, Testosteron (Androsten 3-on-17-ol). Helv chimActa 18:1264–1275

    Article  CAS  Google Scholar 

  • Schänzer W (2004) Abuse of androgens and detection of illegal use. In: Nieschlag E, Behre HM (eds) Testosterone -Action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 715–735

    Chapter  Google Scholar 

  • Schaison G, Couzinet B. (1998) Percutaneous dihydrotestoster-one treatment In: Nieschlag E, Behre HM (eds) Testosterone — caction, deficiency, substitution, 2nd edn. Springer, Heidelberg, pp 423–436

    Google Scholar 

  • Schubert M, Minnemann T, Hübler D, Rouskova D, Christoph A, Oettel M, Ernst M, Mellinger U, Krone W, Jockenhövel F (2004) Intramuscular testosterone undecanoate: Pharma-cokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadism. J Clin Endocrinol Metab 89:5429–5434

    Article  CAS  PubMed  Google Scholar 

  • Schürmeyer T, Wickings EJ, Freischem CW, Nieschlag E (1983) Saliva and serum testosterone following oral testosterone undecanoate administration in normal and hypogonadal men. Acta Endocrinol 102:456–462

    PubMed  Google Scholar 

  • Shores MM, Matsumoto AM, Sloan KL, Kivlaha DR (2006) Low serum testosterone and mortality in male veterans. Arch Intern Med 166:1660–1665

    Article  CAS  PubMed  Google Scholar 

  • Snyder PJ, Peachey H, Hannoush P, Berlin JA, Loh L, Holmes JH, Dlewati A, Staley J, Santanna J, Kapoor SC, Attie MF, Haddad JG Jr, Strom BL (1999) Effect of testosterone treatment on bone mineral density in men over 65 years of age. J Clin Endocrinol Metab 84:1966–1972

    Article  CAS  PubMed  Google Scholar 

  • Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N (2000) Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 85:4500–4510

    Article  CAS  PubMed  Google Scholar 

  • von Eckardstein A, Wu FCW (2004) Testosterone and cardiovascular diseases. In: Nieschlag E, Behre HM (eds) Testosterone -action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 297–332

    Chapter  Google Scholar 

  • von Eckardstein S, Nieschlag E (2002) Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12 weeks: a phase II study. J Androl 23:419–425

    Google Scholar 

  • Wang C, Cunningham G, Dobs A, IranmaneshA, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS (2004) Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 89:2085–2098

    Article  CAS  PubMed  Google Scholar 

  • Wang C, Nieschlag E, Swerdloff R, Behre HM, Hellstrom WJ, Gooren LJ, Kaufmann JM, Legros JJ, Lunenfeld B, Morales A, Morley JE, Schulman C, Thompson IM, Weidner W, Wu FC (2008) Investigation, treatment and monitoring of late-onset hypoginadism in males. Int J Androl [Epub ahead of print]

    Google Scholar 

  • Wang L, Shi DC, Lu SY, Fang RY (1991) The therapeutic effect of domestically produced testosterone undecanoate in Klinefelter syndrome. New Drugs Mark 8:28–32

    CAS  Google Scholar 

  • World Health Organization, Nieschlag E, Wang Ch, Handelsman DJ, Swerdloff RS, Wu FCW, Einer-Jensen N, Khanna J, Waites GMH (eds) (1992) Guidelines for the use of androgens. WHO, Geneva

    Google Scholar 

  • Wilson JD (1988) Androgen abuse by athletes. Endocr Rev 9:181–199

    Article  CAS  PubMed  Google Scholar 

  • Zitzmann M, Nieschlag E (2004) Androgens and bone metabolism. In: Nieschlag E, Behre HM (eds) Testosterone — action, deficiency, substitution, 3rd edn. Cambridge University Press, Cambridge, pp 233–254

    Chapter  Google Scholar 

  • Zitzmann M, Nieschlag E (2007) Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men. J Clin Endocrinol Metab. 92:3844–3853

    Article  CAS  PubMed  Google Scholar 

  • Zitzmann M, Weckesser M, Schober O, Nieschlag E (2001) Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy. Exp Clin Endocrinol Diabetes 109:302–304

    Article  CAS  PubMed  Google Scholar 

  • Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E (2003) Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 88:2049–2054

    Article  CAS  PubMed  Google Scholar 

  • Zitzmann M, Faber D, Nieschlag E (2006) Association of specific symptoms and metabolic risks with serum testosterone in older men. J Clin Endocrinol Metab 91:4335–4343

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centre of Reproductive Medicine and Andrology of the University, Domagkstr. 11, Münster, 48149, Germany

    Eberhard Nieschlag

  2. Centre for Reproductive Medicine and Andrology of the University, Ernst-Grube-Str. 40, Halle, 06120, Germany

    Hermann M. Behre

Authors
  1. Eberhard Nieschlag
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hermann M. Behre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eberhard Nieschlag .

Editor information

Editors and Affiliations

  1. Centre for Reproductive Medicine and Andrology of the University, Domagkstr. 11, Mönster, 48149, Germany

    Eberhard Nieschlag  & Susan Nieschlag  & 

  2. Centre for Reproductive Medicine and Andrology of the University, Ernst-Grube-Str. 40, Halle/Saale, 06120, Germany

    Hermann M. Behre

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Nieschlag, E., Behre, H.M. (2010). Testosterone Therapy. In: Nieschlag, E., Behre, H.M., Nieschlag, S. (eds) Andrology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-78355-8_21

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-78355-8_21

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-78354-1

  • Online ISBN: 978-3-540-78355-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation